Humana Rallies as Analysts Signal Medicare Margin Gains

Key Moments

Humana stock rose 1.4% in pre-market trading after Cantor Fitzgerald upgraded the shares to Overweight from Neutral and lifted its price target to $460 from $300.
Cantor Fitzgerald raised its EPS forecasts to $17.96 for 2027 and $28.27 for 2028, arguing that current valuation overlooks expected Medicare Advantage margin recovery.
The move higher came even as major U.S. equity benchmarks traded lower, underscoring Humana’s relative strength in a risk-off market environment.

Analyst Upgrade Sparks Pre-Market Move

Humana Inc. (NYSE:HUM) traded higher in pre-open activity, gaining 1.4% after Cantor Fitzgerald shifted its stance on the health insurer to Overweight from Neutral. The firm simultaneously boosted its price objective on the stock to $460 from $300, pointing to increased confidence in the company’s ability to restore Medicare Advantage profitability and enhance its STARS quality ratings.

The research firm highlighted a more constructive outlook on Humana’s Medicare Advantage business as a key driver of the call, framing the stock’s advance as a reaction to a perceived turn in fundamentals tied to margins and plan quality metrics.

Revised EPS Outlook and Valuation View

As part of the upgrade, Cantor Fitzgerald significantly increased its earnings per share projections. The firm now anticipates EPS of $17.96 for 2027 and $28.27 for 2028, up from prior expectations of $15.86 and $25.38, respectively. These revisions followed direct discussions with major Medicare Advantage operators and sector specialists focused on STARS performance and bid strategies.

Cantor Fitzgerald argued that Humana’s current valuation does not adequately reflect the anticipated improvement in Medicare Advantage margins over the next two years. The firm noted that at recent trading levels, Humana is valued at roughly 9.9 times the implied midpoint of its 2028 earnings framework, which it described as materially below the company’s historical price-to-earnings multiple of about 18 times.

Metric	Previous Estimate	New Estimate
2027 EPS forecast	$15.86	$17.96
2028 EPS forecast	$25.38	$28.27
Price target	$300	$460

Building Momentum in Analyst Sentiment

The Cantor Fitzgerald upgrade adds to a series of favorable analyst actions on Humana. Barclays had previously raised its rating to Overweight and set a price target of $515 in late September, while Wolfe Research has reiterated an Outperform view with a $450 target.

This sequence of positive calls reflects what has become a multi-week trend of rising analyst confidence in Humana’s ability to stabilize and improve its Medicare Advantage margins.

Strategic Shifts in Medicare Advantage Offering

Humana has also taken steps on the product side that have contributed to the constructive narrative. In early October, the company announced an expanded Medicare Advantage plan lineup for 2027. The offering includes $0 in-network primary care visits and lab services, a feature that has been cited as supportive of its strategic repositioning within the Medicare Advantage market.

Relative Strength in a Weak Market Tape

The advance in Humana shares occurred against a softer broader market backdrop. Ahead of the regular session, the S&P 500 was lower by 0.4%, the Dow Jones Industrial Average was down 0.7%, and the Nasdaq was also off 0.7%, indicating a risk-off tone across major indices.

Humana’s pre-market outperformance stood out given ongoing challenges for the healthcare space, including pressures stemming from Medicare funding trends and regulatory uncertainty. The stock was trading well above its prior close of $404.27, with the Cantor Fitzgerald upgrade acting as the immediate catalyst and reinforcing the improving sentiment story around the company’s Medicare margin recovery trajectory.